Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Get questions ready for the SHAM

Now that Patriot has settled with TPL, why aren’t there more MMP license announcements?

From the FAQs on company website

A: While we believe that by settling we have removed a significant obstacle faced by the license program, we also believe the licensing program is influenced by several factors, some of which are more fully described in the Risk Factors section of our annual report on Form 10-K for the year ended may 31, 2011, and the quarterly report on Form 10Q for the period ended August 31, 2011. We encourage the investing public to review these risk factors.

Significant Obstacle: From my notes of the amended complaint PTSC vs TPL

TPL’s response has been to threaten to shut down the licensing program. Further to try to coerce Patriot to loan it more money, TPL has focused on a new strategy of improperly diverting licensing revenue to itself through its licensing division Alliacense, contrary to its authority under the ComAg

Risks: from the 10Q some but not all

We may not receive future revenues from license agreements at all.

We do not anticipate making additional loans to TPL, and its ability to access liquidity from other sources is not certain.

PDS, our joint venture with TPL, has experienced significant declines in revenues while at the same time incurring significant legal costs associated with pending litigation. We expect PDS will fund its operations through licensing revenue.

An adverse decision in litigation or in the re-examination process could have a very significant and adverse effect on our business.

As far as I can tell, these risk factors have always been there. What about the significant obstacle referenced by me above

(emphasis by me)

Share
New Message
Please login to post a reply